Literature DB >> 6800349

Plasma apolipoprotein A-1 absence associated with a marked reduction of high density lipoproteins and premature coronary artery disease.

E J Schaefer, W H Heaton, M G Wetzel, H B Brewer.   

Abstract

A 45-year-old woman with corneal opacification and severe coronary artery disease was noted to have the following plasma lipid levels (mg/dl, +/- SD): total cholesterol 111 +/- 13, triglyceride 62 +/- 6, very low density lipoprotein cholesterol 4 +/- 1, low density lipoprotein cholesterol 106 +/- 14, and high density lipoprotein (HDL) cholesterol 1 +/- 1 (normal, 50 +/- 14). Her two offspring and one brother were found to have HDL cholesterol values (mg/dl) of 23, 20, and 20, respectively. The percentage of cholesterol in the esterified form in the patient's plasma was normal at 70%. Lipoprotein electrophoresis showed no alpha lipoprotein band, and no HDL was detectable when plasma was subjected to analytic ultracentrifugation. Only trace amounts of lipids were noted within the HDL density region following preparative ultracentrifugation. Mean plasma apolipoprotein (apo) A-ll, apo B, and apo C-ll plasma levels were 13.8%, 130.6% and 26.6% of normal, respectively. The ratio of apo B to cholesterol within LDL was elevated. Apo A-l, the major HDL protein constituent, was immunologically undetectable in this patient's plasma. A decreased HDL cholesterol concentration has been associated with premature coronary artery disease. These data indicate that plasma apo A-l absence results in a striking reduction in HDL, is associated with premature coronary artery disease, and represents a new distinct disease entity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6800349     DOI: 10.1161/01.atv.2.1.16

Source DB:  PubMed          Journal:  Arteriosclerosis        ISSN: 0276-5047


  45 in total

1.  ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis.

Authors:  Anne M Fagan; Erin Christopher; Jennie W Taylor; Maia Parsadanian; Michael Spinner; Melanie Watson; John D Fryer; Suzanne Wahrle; Kelly R Bales; Steven M Paul; David M Holtzman
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

Review 2.  Indications for lipid-lowering drugs.

Authors:  J Davignon
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 3.  Genetic basis of lipoprotein disorders.

Authors:  J L Breslow
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

4.  Homozygous hypobetalipoproteinemia: a disease distinct from abetalipoproproteinemia at the molecular level.

Authors:  R S Ross; R E Gregg; S W Law; J C Monge; S M Grant; K Higuchi; T J Triche; J Jefferson; H B Brewer
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

5.  Do mutations causing low HDL-C promote increased carotid intima-media thickness?

Authors:  Michael Miller; Jeffrey Rhyne; Seung Ho Hong; Gina Friel; Christina Dolinar; Ward Riley
Journal:  Clin Chim Acta       Date:  2006-10-07       Impact factor: 3.786

Review 6.  Molecular regulation of HDL metabolism and function: implications for novel therapies.

Authors:  Daniel J Rader
Journal:  J Clin Invest       Date:  2006-12       Impact factor: 14.808

7.  Formation of apolipoprotein-specific high-density lipoprotein particles from lipid-free apolipoproteins A-I and A-II.

Authors:  M A Clay; D A Cehic; D H Pyle; K A Rye; P J Barter
Journal:  Biochem J       Date:  1999-02-01       Impact factor: 3.857

8.  Substitution of the carboxyl-terminal domain of apo AI with apo AII sequences restores the potential of HDL to reduce the progression of atherosclerosis in apo E knockout mice.

Authors:  P Holvoet; S Danloy; E Deridder; M Lox; H Bernar; A Dhoest; D Collen
Journal:  J Clin Invest       Date:  1998-07-15       Impact factor: 14.808

Review 9.  A novel amyloidogenic variant of apolipoprotein AI: implications for a conformational change leading to cardiomyopathy.

Authors:  M T Walsh
Journal:  Am J Pathol       Date:  1999-01       Impact factor: 4.307

10.  Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency.

Authors:  K Ikewaki; D J Rader; T Sakamoto; M Nishiwaki; N Wakimoto; J R Schaefer; T Ishikawa; T Fairwell; L A Zech; H Nakamura
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.